

Huei Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9062468/publications.pdf>

Version: 2024-02-01

48
papers

4,007
citations

201674

27
h-index

189892

50
g-index

50
all docs

50
docs citations

50
times ranked

6111
citing authors

#	ARTICLE	IF	CITATIONS
1	<scp>PD-L1</scp> expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating <scp>TGF-1</scp>/<scp>SMAD4</scp> expression. Thoracic Cancer, 2022, 13, 1322-1332.	1.9	5
2	Novel function of PERP-428 variants impacts lung cancer risk through the differential regulation of PTEN/MDM2/p53-mediated antioxidant activity. Free Radical Biology and Medicine, 2021, 167, 307-320.	2.9	7
3	Association of <scp>i>hOGG1</i>-Cys</scp> variants with occurrence of <scp>p53</scp> and <scp>i>EGFR</i></scp> deletion mutations in non-small cell lung cancer. Thoracic Cancer, 2021, 12, 534-538.	1.9	3
4	Cytoplasmic, but not nuclear <scp>Nrf2</scp> expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer. Thoracic Cancer, 2020, 11, 1904-1910.	1.9	6
5	Cytoplasmic p27^{Kip1} promotes tumorigenesis via suppression of RhoB activity. Journal of Pathology, 2019, 247, 60-71.	4.5	8
6	Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer. Pathology Research and Practice, 2019, 215, 801-806.	2.3	18
7	Hepatitis B virus X protein represses LKB1 expression to promote tumor progression and poor postoperative outcome in hepatocellular carcinoma. Surgery, 2018, 163, 1040-1046.	1.9	9
8	PSMD4 is a novel therapeutic target in chemoresistant colorectal cancer activated by cytoplasmic localization of Nrf2. Oncotarget, 2018, 9, 26342-26352.	1.8	15
9	MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Oncotarget, 2018, 9, 13758-13767.	1.8	24
10	Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression. International Journal of Biological Sciences, 2018, 14, 47-56.	6.4	25
11	A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics, 2018, 8, 1256-1269.	10.0	34
12	PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression. Oncotarget, 2018, 9, 4637-4646.	1.8	43
13	Targeting insulin-like growth factor-binding protein-3 by microRNA-125b promotes tumor invasion and poor outcomes in non-small-cell lung cancer. Tumor Biology, 2017, 39, 101042831769431.	1.8	12
14	Prostate Cancer Mortality-To-Incidence Ratios Are Associated with Cancer Care Disparities in 35 Countries. Scientific Reports, 2017, 7, 40003.	3.3	68
15	An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling. European Journal of Cancer, 2017, 85, 95-105.	2.8	26
16	A combination of anti-PD-L1 <scp>mA</scp>b plus Lm-LLO</scp>-E6 vaccine efficiently suppresses tumor growth and metastasis in <scp>HPV</scp>-infected cancers. Cancer Medicine, 2017, 6, 2052-2062.	2.8	21
17	The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in <i>KRAS</i>-wild-type colorectal cancer. Theranostics, 2017, 7, 1114-1132.	10.0	43
18	PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells. Oncology Reports, 2017, 38, 1115-1123.	2.6	32

#	ARTICLE	IF	CITATIONS
19	A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine to suppress tumor growth and metastasis in HPV-infected cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e23175-e23175.	1.6	1
20	DDX3 promotes tumor invasion in colorectal cancer via the CK1 μ /Dvl2 axis. <i>Scientific Reports</i> , 2016, 6, 21483.	3.3	33
21	Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4. <i>Free Radical Biology and Medicine</i> , 2016, 95, 121-132.	2.9	32
22	PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation. <i>Clinical Cancer Research</i> , 2016, 22, 5370-5382.	7.0	39
23	MiR-30c-2* negative regulated MTA-1 expression involved in metastasis and drug resistance of HPV-infected non-small cell lung cancer. <i>Surgery</i> , 2016, 160, 1591-1598.	1.9	9
24	PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β -catenin-mediated stemness. <i>Scientific Reports</i> , 2016, 6, 34933.	3.3	27
25	Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer. <i>Tumor Biology</i> , 2016, 37, 4017-4023.	1.8	8
26	DDX3 enhances oncogenic KRAS-induced tumor invasion in colorectal cancer via the β -catenin/ZEB1 axis. <i>Oncotarget</i> , 2016, 7, 22687-22699.	1.8	40
27	Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2. <i>Oncotarget</i> , 2016, 7, 32362-32374.	1.8	38
28	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0142656.	2.5	176
29	Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression. <i>Toxicology Letters</i> , 2015, 237, 46-54.	0.8	35
30	MicroRNA-184 Deregulated by the MicroRNA-21 Promotes Tumor Malignancy and Poor Outcomes in Non-small Cell Lung Cancer via Targeting CDC25A and c-Myc. <i>Annals of Surgical Oncology</i> , 2015, 22, 1532-1539.	1.5	39
31	MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF- κ B/Snail/Bcl-2 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 79, 127-137.	2.9	36
32	Paxillin promotes colorectal tumor invasion and poor patient outcomes via ERK-mediated stabilization of Bcl-2 protein by phosphorylation at Serine 87. <i>Oncotarget</i> , 2015, 6, 8698-8708.	1.8	23
33	NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKK β /NF- κ B activation. <i>Oncotarget</i> , 2015, 6, 14274-14289.	1.8	15
34	Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2. <i>Oncotarget</i> , 2015, 6, 41692-41705.	1.8	105
35	Up-Regulation of FOXM1 by E6 Oncoprotein through the MZF1/NKX2-1 Axis Is Required for Human Papillomavirus-Associated Tumorigenesis. <i>Neoplasia</i> , 2014, 16, 961-971.	5.3	44
36	MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of β -catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer. <i>Carcinogenesis</i> , 2014, 35, 2175-2182.	2.8	46

#	ARTICLE	IF	CITATIONS
37	Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. <i>Carcinogenesis</i> , 2014, 35, 1823-1829.	2.8	53
38	IL-10 Promotes Tumor Aggressiveness via Upregulation of CIP2A Transcription in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 4092-4103.	7.0	59
39	Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. <i>Cancer</i> , 2013, 119, 3367-3376.	4.1	17
40	The APE1 Asp/Asp Genotype and the Combination of APE1 Asp/Asp and hOGG1-Cys Variants Are Associated With Increased p53 Mutation in Non-Small Cell Lung Cancer. <i>Journal of Epidemiology</i> , 2012, 22, 537-542.	2.4	13
41	Loss of TIMP-3 Promotes Tumor Invasion via Elevated IL-6 Production and Predicts Poor Survival and Relapse in HPV-Infected Non-Small Cell Lung Cancer. <i>American Journal of Pathology</i> , 2012, 181, 1796-1806.	3.8	49
42	Reduced p21WAF1/CIP1 via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus-Associated Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 1895-1905.	7.0	83
43	A Polymorphic 844T/C in FasL Promoter Predicts Survival and Relapse in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5991-5999.	7.0	55
44	clAP2 Upregulated by E6 Oncoprotein via Epidermal Growth Factor Receptor/Phosphatidylinositol 3-Kinase/AKT Pathway Confers Resistance to Cisplatin in Human Papillomavirus 16/18-Infected Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5200-5210.	7.0	67
45	Paxillin Predicts Survival and Relapse in Non-Small Cell Lung Cancer by MicroRNA-218 Targeting. <i>Cancer Research</i> , 2010, 70, 10392-10401.	0.9	121
46	Human Telomerase Reverse Transcriptase Activated by E6 Oncoprotein Is Required for Human Papillomavirus-16/18-Infected Lung Tumorigenesis. <i>Clinical Cancer Research</i> , 2008, 14, 7173-7179.	7.0	32
47	Human Papillomavirus 16/18 E6 Oncoprotein Is Expressed in Lung Cancer and Related with p53 Inactivation. <i>Cancer Research</i> , 2007, 67, 10686-10693.	0.9	115
48	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2005, 97, 339-346.	6.3	2,194